Should I buy or sell BioLife Solutions stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLFS shares. View BLFS analyst ratings or view top-rated stocks .

What is BioLife Solutions' stock price target for 2024?

4 Wall Street research analysts have issued 12-month price targets for BioLife Solutions' shares. Their BLFS share price targets range from $22.00 to $25.00. On average, they anticipate the company's stock price to reach $23.40 in the next year. This suggests a possible upside of 49.9% from the stock's current price. View analysts price targets for BLFS or view top-rated stocks among Wall Street analysts .

How have BLFS shares performed in 2024?

BioLife Solutions' stock was trading at $16.25 at the start of the year. Since then, BLFS stock has decreased by 3.9% and is now trading at $15.61. View the best growth stocks for 2024 here .

Are investors shorting BioLife Solutions?

BioLife Solutions saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,200,000 shares, an increase of 5.6% from the March 15th total of 3,030,000 shares. Based on an average trading volume of 412,500 shares, the days-to-cover ratio is currently 7.8 days. View BioLife Solutions' Short Interest .

When is BioLife Solutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our BLFS earnings forecast .

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) released its quarterly earnings data on Thursday, February, 29th. The medical equipment provider reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.02. The medical equipment provider had revenue of $32.73 million for the quarter, compared to analyst estimates of $32.70 million. BioLife Solutions had a negative net margin of 46.37% and a negative trailing twelve-month return on equity of 13.36%.

What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $95.5 million-$100.0 million, compared to the consensus revenue estimate of $121.4 million.

What is Mike Rice's approval rating as BioLife Solutions' CEO?

14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com . Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend.

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU) , AbbVie (ABBV) , Cara Therapeutics (CARA) , Gilead Sciences (GILD) , Pfizer (PFE) , Rigel Pharmaceuticals (RIGL) , Sorrento Therapeutics (SRNE) , Twilio (TWLO) and Verastem (VSTM) .

Who are BioLife Solutions' major shareholders?

BioLife Solutions' stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.29%), Penbrook Management LLC (0.09%) and Register Financial Advisors LLC (0.01%). Insiders that own company stock include Aby J Mathew, Aby J Mathew , Amy Duross, Andrew G Hinson, Andrew G Hinson , Casdin Partners Master Fund, L, Geraint Phillips, Greef Roderick De , Joseph C Schick , Karen A Foster, Karen A Foster , Marcus Schulz , Michael Rice , Of The University Of C Regents, Sarah Aebersold , Todd Berard and Troy Wichterman . View institutional ownership trends .

How do I buy shares of BioLife Solutions?

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BLFS

BioLife Solutions (BLFS) Stock Price, News & Analysis

→ Chances are you know the firms on this list (From WealthPress) (Ad)

Free BLFS Stock Alerts

$15.61

-0.25 (-1.58%)

(As of 11:25 AM ET)

Compare

Today's Range: $15.54
▼
$16.01
50-Day Range: $15.14
▼
$18.82
52-Week Range: $8.92
▼
$24.50

Volume: 64,835 shs
Average Volume: 400,925 shs
Market Capitalization: $707.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $23.40

Get BioLife Solutions alerts:

BioLife Solutions MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 49.9% Upside
$23.40 Price Target
Short Interest: Bearish
7.06% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.57
Based on 9 Articles This Week
Insider Trading: Selling Shares
$706,758 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.60) to ($0.51) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.69 out of 5 stars

Medical Sector

585th out of 918 stocks

Electromedical Equipment Industry

9th out of 19 stocks

3.5

Analyst's Opinion

Consensus Rating
BioLife Solutions has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
BioLife Solutions has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.06% of the outstanding shares of BioLife Solutions have been sold short.
Short Interest Ratio / Days to Cover
BioLife Solutions has a short interest ratio ("days to cover") of 7.8.
Change versus previous month
Short interest in BioLife Solutions has recently increased by 5.61%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
BioLife Solutions does not currently pay a dividend.
Dividend Growth
BioLife Solutions does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BLFS.

2.0

News and Social Media Coverage

News Sentiment
BioLife Solutions has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for BioLife Solutions this week, compared to 2 articles on an average week.
MarketBeat Follows
Only 2 people have added BioLife Solutions to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioLife Solutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $706,758.00 in company stock.
Percentage Held by Insiders
Only 2.70% of the stock of BioLife Solutions is held by insiders.
Percentage Held by Institutions
93.24% of the stock of BioLife Solutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for BioLife Solutions are expected to grow in the coming year, from ($0.60) to ($0.51) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioLife Solutions is -10.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioLife Solutions is -10.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BioLife Solutions has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Darwin

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your report

About BioLife Solutions Stock (NASDAQ:BLFS)

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

BLFS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BLFS Stock News Headlines

April 19, 2024 | insidertrades.com

Todd Berard Sells 10,000 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

April 4, 2024 | insidertrades.com

Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sells 4,000 Shares of Stock

April 19, 2024 | DTI (Ad)

Don’t expose yourself to stocks during the week

The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.

April 18, 2024 | finance.yahoo.com

Insider Sell: Chief Marketing Officer Todd Berard Sells 10,000 Shares of BioLife Solutions Inc ...

April 18, 2024 | prnewswire.com

BioLife Solutions Announces the Divestiture of its Stirling Freezer Business

April 17, 2024 | americanbankingnews.com

BioLife Solutions, Inc. (NASDAQ:BLFS) Short Interest Up 5.6% in March

April 4, 2024 | markets.businessinsider.com

Buy Rating on BioLife Solutions: Focused Growth and Market Leadership Post-Divestiture

March 30, 2024 | msn.com

Powell: ‘No reason’ to think economy is close to recession

April 19, 2024 | DTI (Ad)

Don’t expose yourself to stocks during the week

March 29, 2024 | finance.yahoo.com

Investors in BioLife Solutions (NASDAQ:BLFS) have unfortunately lost 49% over the last three years

March 27, 2024 | finance.yahoo.com

Corporate Insiders Are Selling These 10 Small-Cap Stocks

March 14, 2024 | finance.yahoo.com

Director Amy Duross Sells 11,200 Shares of BioLife Solutions Inc (BLFS)

March 13, 2024 | finance.yahoo.com

Insider Sell: Chief Marketing Officer Todd Berard Sells 7,508 Shares of BioLife Solutions Inc (BLFS)

March 8, 2024 | finance.yahoo.com

When Will BioLife Solutions, Inc. (NASDAQ:BLFS) Become Profitable?

March 4, 2024 | finance.yahoo.com

BioLife Solutions to Present at TD Cowen and Key Bank Investor Conferences

March 2, 2024 | finance.yahoo.com

BioLife Solutions, Inc. (NASDAQ:BLFS) Q4 2024 Earnings Call Transcript

March 1, 2024 | finanznachrichten.de

BioLife Solutions, Inc.: BioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial Results

March 1, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Chimerix (CMRX)

March 1, 2024 | finance.yahoo.com

Q4 2023 BioLife Solutions Inc Earnings Call

February 29, 2024 | benzinga.com

Recap: BioLife Solns Q4 Earnings

February 29, 2024 | prnewswire.com

BioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial Results

February 28, 2024 | msn.com

BioLife Solutions Q4 2023 Earnings Preview

February 28, 2024 | benzinga.com

Earnings Preview For BioLife Solns

February 28, 2024 | markets.businessinsider.com

Here's what to expect from Biolife Solutions's earnings

February 25, 2024 | msn.com

Peter Thiel resigns from AbCellera board for personal reasons

February 21, 2024 | finance.yahoo.com

BLFS Jul 2024 12.500 call

February 20, 2024 | finance.yahoo.com

BioLife Solutions to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update on February 29, 2024

See More Headlines

Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Electromedical equipment
Sub-Industry: N/A
Current Symbol: NASDAQ:BLFS
CUSIP: N/A
CIK: 834365
Web: www.biolifesolutions.com
Phone: (425) 402-1400
Fax: 425-402-1433
Employees: 409
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $23.40
High Stock Price Target: $25.00
Low Stock Price Target: $22.00
Potential Upside/Downside: +47.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.52)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-66,430,000.00
Net Margins: -46.37%
Pretax Margin: -46.25%
Return on Equity: -13.36%
Return on Assets: -10.83%

Debt

Debt-to-Equity Ratio: 0.06
Current Ratio: 2.86
Quick Ratio: 1.83

Sales & Book Value

Annual Sales: $143.27 million
Price / Sales: 5.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.67 per share
Price / Book: 2.07

Miscellaneous

Outstanding Shares: 45,300,000
Free Float: 44,077,000
Market Cap: $718.46 million
Optionable: Optionable
Beta: 1.67

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. Roderick de Greef (Age 64)
CEO & Chairman
Comp: $1.63M
Mr. Troy Wichterman (Age 39)
Chief Financial Officer
Comp: $485.2k
Ms. Karen Foster (Age 64)
Chief Quality & Operations Officer
Comp: $395.2k
Dr. Aby J. Mathew Ph.D. (Age 52)
Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer
Comp: $448.2k
Mr. Michael P. Rice (Age 61)
Consultant
Comp: $1.3M
Mr. Todd Berard (Age 55)
Chief Marketing Officer
Comp: $286.49k
Ms. Sarah Aebersold J.D. (Age 47)
Chief Human Resources Officer
Mr. Garrie Richardson B.Sc. (Age 51)
M.B.A., Chief Revenue Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BLFS Stock Analysis - Frequently Asked Questions

Should I buy or sell BioLife Solutions stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLFS shares.
View BLFS analyst ratings or view top-rated stocks.
What is BioLife Solutions' stock price target for 2024?: 4 Wall Street research analysts have issued 12-month price targets for BioLife Solutions' shares. Their BLFS share price targets range from $22.00 to $25.00. On average, they anticipate the company's stock price to reach $23.40 in the next year. This suggests a possible upside of 49.9% from the stock's current price.
View analysts price targets for BLFS or view top-rated stocks among Wall Street analysts.
How have BLFS shares performed in 2024?: BioLife Solutions' stock was trading at $16.25 at the start of the year. Since then, BLFS stock has decreased by 3.9% and is now trading at $15.61.
View the best growth stocks for 2024 here.
Are investors shorting BioLife Solutions?: BioLife Solutions saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,200,000 shares, an increase of 5.6% from the March 15th total of 3,030,000 shares. Based on an average trading volume of 412,500 shares, the days-to-cover ratio is currently 7.8 days.
View BioLife Solutions' Short Interest.
When is BioLife Solutions' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our BLFS earnings forecast.
How were BioLife Solutions' earnings last quarter?: BioLife Solutions, Inc. (NASDAQ:BLFS) released its quarterly earnings data on Thursday, February, 29th. The medical equipment provider reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.02. The medical equipment provider had revenue of $32.73 million for the quarter, compared to analyst estimates of $32.70 million. BioLife Solutions had a negative net margin of 46.37% and a negative trailing twelve-month return on equity of 13.36%.

What guidance has BioLife Solutions issued on next quarter's earnings?: BioLife Solutions updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $95.5 million-$100.0 million, compared to the consensus revenue estimate of $121.4 million.
What is Mike Rice's approval rating as BioLife Solutions' CEO?: 14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend.
What other stocks do shareholders of BioLife Solutions own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).
Who are BioLife Solutions' major shareholders?: BioLife Solutions' stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.29%), Penbrook Management LLC (0.09%) and Register Financial Advisors LLC (0.01%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Amy Duross, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Geraint Phillips, Greef Roderick De, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Sarah Aebersold, Todd Berard and Troy Wichterman.
View institutional ownership trends.
How do I buy shares of BioLife Solutions?: Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BLFS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial